AbbVie Inc.
ABBV
Below: live stock price for AbbVie Inc. (ABBV), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
AbbVie Inc. (ABBV) trades at 260.39 USD on investpig.
- Prev close
- $261.72
- Volume (24h)
- $149.56M
- Market cap
- $460.14B
- Currency
- USD
Score
Insufficient data
- Value—
- Quality—
- Momentum—
- Growth—
- Risk—
- Dividend—
- Liquidity—
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 263.9464 +0.85%
- +20 bars
- 267.0494 +2.04%
- +60 bars
- 268.2596 +2.50%
- +120 bars
- 268.304 +2.52%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0368 USD.
Interpretation
Price sits near the upper third of the recent range, trend is sloping upward.
Descriptive observation — not investment advice.
Price report
How this asset has actually moved over the last 252 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 26.5%
- Max drawdown
- -19.2%
- Below period high
- -2.1%
- Best day
- +6.25%
- Worst day
- -5.20%
- Up days
- 49%
- Current streak
- 3 up
- Typical day swing
- 2.3%
- Volume vs average
- -25%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 267.47 high → 215.37 low · 60 bars
- ResistanceFib +161.8% extensionnot reached351.7678 USD+34.41% from current
- ResistanceFib +100% extensionnot reached319.57 USD+22.10% from current
- ResistanceFib +61.8% extensionnot reached299.6678 USD+14.50% from current
- ResistanceFib +27.2% extensionnot reached281.6412 USD+7.61% from current
- Current261.72 USD
- SupportFib 23.6% retracementNearesttested 18×255.1744 USD-2.50% from current
- SupportFib 38.2% retracementtested 13×247.5678 USD-5.41% from current
- SupportFib 50% midpointtested 2×241.42 USD-7.76% from current
- SupportFib 61.8% retracementtested 3×235.2722 USD-10.11% from current
- SupportFib 78.6% retracementtested 5×226.5194 USD-13.45% from current
- SupportFib −27.2% extensionnot reached201.1988 USD-23.12% from current
- SupportFib −61.8% extensionnot reached183.1722 USD-30.01% from current
- SupportFib −100% extensionnot reached163.27 USD-37.62% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Recent news
- AbbVie Closes $10.9 Billion Acquisition of Apogee TherapeuticsMT Newswires1h ago
- AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple MyelomaPR Newswire1h ago
- AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary EndpointsMT Newswires56m ago
- AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare ConferencePR Newswire2h ago
- AbbVie Completes Acquisition of Apogee TherapeuticsPR Newswire2h ago
- Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?Zacks4h ago
- AbbVie could take BiTE of Tecvayli market share on Phase III MM winClinical Trials Arena23m ago
- AbbVie (ABBV) Stock Looks Fully Priced Despite A 43% Fair Value GapSimply Wall St.22h ago
Related
Other assets in this category.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,754 USD+1.90%
- 7203.TToyota Motor Corporation3,117 USD-0.51%
- 9984.TSoftBank Group Corp.5,001 USD+1.56%
- 6758.TSony Group Corporation3,895 USD-0.64%
- 6861.TKeyence Corporation77,980 USD-0.05%
- NVDANVIDIA Corporation226.22 USD+0.81%
- AAPLApple Inc.328.995 USD+1.24%
- GOOGLAlphabet Inc.341.6 USD+1.33%
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.